Verona Pharma begins dosing RPL554 in Phase IIb COPD trial

26th July 2017 Uncategorised 0

Patients have begun receiving Verona Pharma’s experimental respiratory drug RPL554 in a Phase IIb trial assessing its potential as a maintenance therapy for chronic obstructive pulmonary disease (COPD).

More: Verona Pharma begins dosing RPL554 in Phase IIb COPD trial
Source: News